Innovestor and Orion are looking for startup and scaleup companies that develop innovative solutions for further drug discovery and development.
We are especially looking for new, promising medical solutions in the following areas:
- Neuropathic pain and other chronic pain conditions
1-4 companies will be chosen to meet and discuss future collaboration with Orion. For these companies, the discussions can open access to, for example, Orion’s networks, know-how, R&D resources, and commercialization possibilities. Orion’s team is committed to bringing their know-how about drug discovery and development and processes to achieve concrete mutual results.
“We are looking for new treatments for unmet needs of the patients, to strengthen our drug discovery and development activities by finding new partners with high-level expertise. With our vast R&D know-how, we want to help your company bring your solution to the next level.”Antti Haapalinna, Vice President, External Science & Partnering and R&D, Orion
Sounds interesting? Send your company information to katri.rutanen(a)innovestor.fi.
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. Orion’s customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Orion’s main market is Finland, and it’s products are marketed in over a hundred countries. All of Orion’s manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo. Orion’s A and B shares are listed on Nasdaq Helsinki.
Innovestor is a Nordic early-stage venture capital investor which also supports corporations in forming cooperation partnerships and mutual business models with startups and scaleups. We are supporting Orion in its efforts to find competitive advantages in new innovations in drug discovery and development.
For more information, please contact:
Katri Rutanen, Service Manager, Corporate Venturing, Innovestor: katri.rutanen(a)innovestor.fi